University of Medicine and Dentistry of New Jersey-Graduate School of Biomedical Sciences at the School of Osteopathic Medicine, Stratford, New Jersey, United States of America.
PLoS One. 2012;7(2):e32383. doi: 10.1371/journal.pone.0032383. Epub 2012 Feb 22.
Parkinson's disease (PD), hallmarked by a variety of motor disorders and neurological decline, is the second most common neurodegenerative disease worldwide. Currently, no diagnostic test exists to identify sufferers, and physicians must rely on a combination of subjective physical and neurological assessments to make a diagnosis. The discovery of definitive blood-borne biomarkers would be a major step towards early and reliable diagnosis. Despite attention devoted to this search, such biomarkers have remained elusive. In the present study, we used human protein microarrays to reveal serum autoantibodies that are differentially expressed among PD and control subjects. The diagnostic significance of each of these autoantibodies was evaluated, resulting in the selection of 10 autoantibody biomarkers that can effectively differentiate PD sera from control sera with a sensitivity of 93.1% and specificity of 100%. PD sera were also distinguishable from sera obtained from Alzheimer's disease, breast cancer, and multiple sclerosis patients with accuracies of 86.0%, 96.6%, and 100%, respectively. Results demonstrate that serum autoantibodies can be used as highly specific and accurate biomarkers for PD diagnosis throughout the course of the disease.
帕金森病（PD）以多种运动障碍和神经功能衰退为特征，是全球第二常见的神经退行性疾病。目前，尚无诊断测试可用于识别患者，医生必须依靠主观的身体和神经评估相结合来做出诊断。发现明确的血液生物标志物将是实现早期和可靠诊断的重要一步。尽管人们对这一研究给予了关注，但这些生物标志物仍然难以捉摸。在本研究中，我们使用人类蛋白质微阵列揭示了在 PD 和对照组之间差异表达的血清自身抗体。评估了每种自身抗体的诊断意义，最终选择了 10 种自身抗体生物标志物，可有效区分 PD 血清和对照血清，其灵敏度为 93.1%，特异性为 100%。PD 血清也可以与来自阿尔茨海默病、乳腺癌和多发性硬化症患者的血清区分开来，准确率分别为 86.0%、96.6%和 100%。结果表明，血清自身抗体可用作 PD 诊断的高度特异性和准确性生物标志物，适用于疾病的整个过程。
